Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 16/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1338714 | 0.91 | GRM4 (0.36) | GRM4RAB9AKDM4ERORC | |
| SCHEMBL1339934 | 0.91 | PTGDR2 (0.39) | GRM4KMT2ANPC1RAB9AMAPT | |
| SCHEMBL1341812 | 0.91 | GRM4 (0.36) | GRM4NPC1RAB9AMAPTHTT | |
| SCHEMBL1341783 | 0.90 | GRM4 (0.36) | GRM4GRIK1KMT2ANPC1RAB9A | |
| SCHEMBL1340258 | 0.89 | MAPT (0.34) | GRM4KMT2AMAPTRORC | |
| SCHEMBL1342604 | 0.89 | GRM4 (0.36) | GRM4 | |
| SCHEMBL1341114 | 0.89 | KMT2A (0.39) | GRM4KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL1342435 | 0.89 | GRM4 (0.38) | GRM4KMT2ANPC1RAB9A | |
| SCHEMBL1340181 | 0.88 | GRIK1 (0.38) | GRM4GRIK1KMT2ANPC1RAB9A | |
| SCHEMBL1343497 | 0.88 | CCNE1 (0.35) | GRM4RAB9ARORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063081-B2 | N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-11-22 | — | — | US | disclosed |
| US-7897628-B2 | {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-03-01 | — | — | US | disclosed |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | GRM4 2551/4885GRIK1 1313/4885KMT2A 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.